PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
38 hedge funds and large institutions have $3.89M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 12 closing their positions.
22% less funds holding
Funds holding: 49 → 38 (-11)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
72% less capital invested
Capital invested by funds: $14M → $3.89M (-$10.1M)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$611K |
| 2 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
+$158K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$76.5K |
| 4 |
UBV
United Bank (Virginia)
Vienna,
Virginia
|
+$10.7K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$3.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
-$450K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$434K |
| 3 |
NLG
New Legacy Group
New York
|
-$144K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$102K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$73K |
PHAS Hedge Fund Activity: Q3 2022 in Review
38 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q3 2022, worth a combined $3.89M — down 72% from $14M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PHAS and 1 opened new positions — a net loss of 11 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was MAI Capital Management, adding an estimated $611K. The largest seller was CHI Advisors, exiting entirely with an estimated $450K sold.
- 38 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q3 2022, down from 49 in Q2 2022.
- Funds reported $3.89M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q3 2022, down 72% quarter-over-quarter.
- 1 fund opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 12 closed out, a net change of -11 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was MAI Capital Management, an estimated $611K added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was CHI Advisors, an estimated $450K sold.
Based on aggregated 13F filings for Q3 2022.